الفهرس 
Gestational Diabetes MellitusOnly 14 pages are availabe for public view
 |  | from | 104 |  |  |
| | | from | 104 | | |
Abstract
The present study included 360 pregnant women who have
been diagnosed as gestational diabetes according to the American
Diabetes Association Criteria (fasting ≥92mg/dl, 1h ≥180 mg/dl
and 2h≥ 153 mg/dl) using 2 or more abnormal plasma glucose
values at 24- 28 week gestation with singleton pregnancy.
The exclusion criteria included pregnant women with
preexisting D.M and underlying diseases known to affect fetal
growth or drug clearance.
Randomly 120 patients were given insulin. Insulin
(Mixtard: mixed human suspension ’crystalline 30% + protamine
insulin 70%) was started at adose of 0.7 U/Kg of actual body
weight, given subcutaneously two times per day that was
increased as needed, 120 patients were given metformin
(metformin was started at an oral dose of 850 mg once or twice
daily with food and the dose was titrated up to a total of 2550
mg/day) and 120 patients were given glibenclamide
(glibenclamide was started at an oral dose of 2.5 to 5 mg/daily
and the dose was titrated up to total dose of 20 mg/day).
Analysis of the results revealed that metformin and
glibenclamide were effective medications for control of blood
glucose in women with GDM who failed to achieve euglycemia
with diet regimen and life style modification.
The present study showed that metformin and
glibenclamide are not associated with increased maternal or
neonatal complications in comparison to insulin.